Viewing nowCombinationExiglumem Sustained-release Tablet 5/1000 mg
Metformin Hydrochloride 1000mg · Dapagliflozin 5mg
Tablet · Prescription medication · Combination
JongkunDang Co., Ltd.

MFDS item code 202107477 · Approved 2021.11.15 · Insurance code 643309190
Improvement of glycemic control in adults with type 2 diabetes
This medication is used in conjunction with diet and exercise to improve blood sugar control in patients with type 2 diabetes. It is particularly suitable for adult patients whose blood sugar is not adequately controlled, where the combination of dapagliflozin and metformin is appropriate. It can also be used in patients with cardiovascular disease or risk factors, but caution should be exercised in these cases by referring to clinical trial information provided by specialists. Overall, this medication helps improve blood sugar control and aids in diabetes management.
The dose of this medicine should be individualized based on the patient's current treatment, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. For patients who have not previously received antidiabetic drug therapy and whose blood glucose is not adequately controlled with monotherapy: When used as initial therapy in patients who have not previously received antidiabetic drug therapy, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. Titrate the dose gradually to reduce gastrointestinal adverse reactions associated with metformin. For patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the patient's current metformin dose or an appropriate dose therapeutically close to it. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. For patients switching to this medicine from combination therapy with dapagliflozin and metformin, this medicine may be started at the doses of dapagliflozin and metformin previously administered. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. When this medicine is used with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switched to it from other antihyperglycemic agents. Because changes may result in altered glycemic control, any change in treatment for patients with type 2 diabetes should be made under careful monitoring. Swallow this medicine whole. Do not crush, cut, or chew it. Occasionally, inactive ingredients in this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more and less than 60 mL/min/1.73 m2 who have no other condition that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, discontinue this medicine immediately. Renal function should be assessed every 3~6 months. Older adults Metformin is excreted by the kidneys, and renal function is more likely to decline in older adults; therefore, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults).
This medication helps control blood sugar; however, it can very rarely cause a serious condition called lactic acidosis, so caution is needed. When taken with other diabetes medications, there can be a risk of hypoglycemia. This drug should not be administered to certain patients. For example, patients with an allergy to its components, those with moderate to severe renal impairment, dehydrated or severely infected patients, patients with type 1 diabetes, and pregnant or breastfeeding women should not take it. Moreover, patients about to undergo surgery or scheduled for tests using contrast agents should discontinue this medication for a certain period. Patients with slightly reduced renal function or those who are dehydrated should use this medication with caution and carefully monitor for hypotension or changes in renal function. Particularly elderly patients or those taking diuretics need to exercise additional caution. Common side effects while taking this medication include genital infections, urinary tract infections, hypoglycemia, dehydration symptoms, dizziness, and dry mouth. Additionally, serious side effects such as ketoacidosis or acute kidney injury may occur rarely, so if any abnormal symptoms arise, prompt consultation with a physician is required. This medication is not recommended for patients with impaired liver function, and alcohol intake should be avoided. Moreover, if blood sugar control fails or an acute condition develops, temporary discontinuation of the medication and appropriate treatment should be administered. Pregnant or breastfeeding women should not take this medication, and safety in pediatric patients has not been established. This medication may interact with other drugs, so particularly when used with diuretics, insulin, or sulfonylureas, dose adjustments may be necessary to reduce the risk of hypoglycemia or dehydration. In the event of an overdose, immediate visit to a medical institution is required for appropriate treatment, and while this medication has minimal impact on driving or operating machinery, dizziness may occur, so caution is advised. Lastly, this medication should be kept out of reach of children and stored in its original container to maintain quality.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air or moisture, so it should be stored in a tightly sealed container. It is important to maintain a storage temperature between 1 to 30 degrees Celsius. Proper storage will help maintain the medication's effectiveness over time.
Pink to dark pink oval sustained-release film-coated tablets, convex on both sides
10 tablets/box [10 tablets/PTP x 1], 30 tablets/bottle, 30 tablets/box [10 tablets/PTP x 3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationMetformin Hydrochloride 1000mg · Dapagliflozin 5mg
Tablet · Prescription medication · Combination
JongkunDang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Dapagliflozin 10mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationMetformin Hydrochloride 500mg · Dapagliflozin 10mg
Tablet · Prescription medication · Combination
Jongkeundang Co., Ltd.
CombinationMetformin Hydrochloride 500mg · Dapagliflozin 5mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.